Arrowhead third-quarter 2010 net loss decreases to $0.

Arrowhead third-quarter 2010 net loss decreases to $0.4 million Arrowhead Research Company today announced financial results because of its fiscal 2010 third quarter ended June 30, 2010. In the 3rd one fourth, we continued to progress our late-stage subsidiaries and build on the momentum we started early in the calendar year, said Christopher Anzalone, Arrowhead’s CEO for inhalation here . In-line with this expectations, Calando’s first-in-class Stage I interim outcomes continue to generate interface possibilities with potential partners. Also, Unidym secured additional joint advancement agreements with two large partners. With the completion of our successful $8.7 million financing, we’ve the capital to aid the disciplined execution of Calando’s and Unidym’s strategies also to invest in future initiatives designed to accelerate development. We have selected already, for diligence and potential acquisition, an exciting technology that addresses the large, underserved obesity market chance. With these achievements, we are making important strategic advancements to create a unique and robust portfolio of nanomedicine companies. THIRD QUARTER FISCAL 2010 AND RECENT COMPANY HIGHLIGHTS: Business highlights: Arrowhead guaranteed $8.7 million in financing through a registered direct offering of share and warrants. Arrowhead rejoined the Russell Microcap Index. Presented interim data from majority-owned subsidiary Calando Pharmaceuticals, Inc.’s Phase I individual trial of its anti-cancer tumor siRNA therapeutic, CALAA-01, at the American Culture for Clinical Oncology Annual Meeting. Unidym entered joint development agreements with Tokyo Guardian and Electron Glass, two global companies developing products for the display sector. Arrowhead signed an option agreement with The University of Texas MD Anderson Cancers Center to negotiate a license in a defined field to a class of compounds that is believed to kill fat cells by particularly targeting the arteries supplying it. Arrowhead added two world-class researchers to its Scientific Advisory Panel, Nobel Prize winner Dr. Lee Hartwell and former FDA Commissioner Dr. Andrew von Eschenbach. Leonardo Biosciences attained $2.5 million in financing from the Texas Emerging Technology Fund and recruited Dr. Bruce Provided as its Chief Executive Officer. Financial highlights: Decreased consolidated quarterly operating expenditures by 53 percent versus the prior year’s quarter from $4.9 million to $2.3 million. Decreased, on a consolidated basis, cash found in operating activities from $12.7 million in the first nine months of 2009 to $5.2 million in the first nine months of 2010. Related StoriesOvarian cancer patients with a brief history of oral contraceptive use possess better outcomesNew antenna-like device makes breast cancer surgery less complicated for surgeonsSausages With Antioxidants From Berries TO AVOID CancerSELECTED FISCAL 2010 THIRD QUARTER FINANCIAL RESULTS For the quarter ended June 30, 2010, Arrowhead reported income of $134,000, compared with $2.6 million in the quarter ended June 30, 2009. The prior period revenue included $2.4 million related to revenue from a permit agreement between Calando and Cerulean Pharma, Inc. Which was not repeated in the current period. Income at Unidym was comparable to the last period. Total operating expenses for the one fourth ended June 30, 2010 were $2.3 million, a loss of $2.6 million from $4.9 million during the quarter ended June 30, 2009. The significant decrease in operating expenditures was due to measures undertaken by administration during 2009 to streamline its businesses and better align its cost structure with its capital resources. June 30 Net reduction for the quarter ended, 2010 was $0.4 million, or $0.01 per talk about based on 64.6 million weighted average shares outstanding. This compares with a net loss of $2.5 million, or $0.6 per share based on 43.4 million weighted average shares outstanding, june 30 for the quarter ended, 2009. In addition to the change in income and operating expenses, a non-cash gain of $1.6 million was recorded as the noticeable change in value of a derivative liability.

http://www.proventil100.com

Arthritis Treatment The treatment of arthritis depends on which particular type of arthritis exists, its location, severity, persistence, and any underlying background medical conditions of the individual. Each treatment program must be customized for the individual patient. Treatment programs can incorporate home remedies, nonprescription and prescription medications, joint injections, and surgical functions. Some treatment applications involve fat loss and avoiding activities that exert excessive stress on the joint. The goal of treatment of arthritis can be to lessen joint pain and inflammation while preventing damage and improving and maintaining joint function.

Other articles from category "herbal medicine":

Random articles